Welcome to MSM Protein Technologies
MSM is pleased to announce the appointment of Dr. Edward Kislauskis to its Scientific Advisory Board. Dr. Kislauskis is an expert in preclinical research and a recognized thought leader on the topic of animal models of human diseases. He is the founder and CEO of Nereus Life Sciences (Weymouth), and previously co-founder and VP for Research for 3 other companies: Biomedical Research Models (Worcester/Springfield), Hygeia Therapeutics (Holden) and Endocellutions (Marshfield). Dr. Kislauskis received his PhD in molecular genetics and postdoctoral training in cell biology at the University of Massachusetts Medical School where he was appointed Assistant Professor of Cell Biology and Pathology. Dr. Albert Zlotnik, the Chairman of the SAB said, "MSM is at a critical juncture where expertise in pre-clinical development is crucial to the company's evolution. Dr. Kislauskis' expertise will prove invaluable to the Company's evolutions from a discovery phase company to a development company."
We are pleased to announce that MSM has satisfied the first pre-clinical milestones in its collaboration with Debiopharm of Lausanne Switzerland. Debiopharm has determined that antibodies generated by MSM have satisfied the target molecular profile as stipulated in our collaboration agreement and the project has moved into the next phase of development.
MSM Protein Technologies is an emerging biotechnology company with a proprietary suite of tools for drug discovery of functional antibodies and proteins against multi-spanning membrane proteins. MSM maximizes the prospect for discovery of drug candidates that bind precisely to GPCRs, ion channels and transporters, a difficult but critically important class of targets for therapeutic intervention.